Compare Mercadolibre Inc (MELI) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs 10X Genomics Inc — how do they compare? Mercadolibre Inc trades at $1,817.68 (market cap $92.90B), while 10X Genomics Inc trades at $46.61 (market cap $5.48B). The key difference: Mercadolibre Inc is far larger — about 17× 10X Genomics Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals.
| MELI | TXG | |
|---|---|---|
Market Cap | $92.90B | $5.48B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.51K | $45.80 |
52-Week Low | $1.55K | $11.34 |
Enterprise Value | $99.79B | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,832.29, up 1.01% in the last session, while showing a bearish technical signal overall. The company reported strong revenue growth, with 2025 revenue reaching $28.89 billion, though recent quarterly EPS results have missed expectations. Operating cash flow improved significantly to $12.12 billion in 2025, and analyst sentiment remains strongly positive with a consensus price target of $2,230.
The outlook for MELI is supported by robust top-line expansion and strategic investments in logistics and fintech, but near-term margin pressure and recent earnings misses present risks. The stock offers growth potential in Latin American e-commerce and digital payments, balanced by competitive and execution challenges in a dynamic market environment.
TXG trades at $43.18, down 1.28% today, with a bullish technical signal and positive earnings momentum. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining a strong gross margin of 69.6%. Recent acquisitions and partnerships with Cleveland Clinic demonstrate strategic expansion in genomic diagnostics.
The outlook remains cautiously optimistic with analyst consensus at Buy (45%) and price target of $39.14. Key risks include continued negative profitability metrics and high valuation multiples, while catalysts include upcoming Q2 2026 earnings and platform adoption growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
